Skip to main content
ANIK logo

ANIK · Anika Therapeutics, Inc.

Track ANIK — free
$13.62 +0.77 (+5.99%) At close · Nov 18
Market Cap
$182.44M
Shares
13.40M
Volume · Nov 18 119.01K Avg daily vol (3M) 107.13K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.62 Open$12.78 Day$12.76–13.84 52W close$9.13–22.03 Avg vol 30d118K Short int324K · 2.4% of shares · 3.1d Short vol56% Last earningsNov 6, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 6
Earnings call
Revenue rises 10%; 2026 outlook raised, HylaFast PMA not approvable

Anika reported third-quarter revenue of $30.6 million, up 10%, and gross margin of 62%, raising 2026 revenue growth guidance to 6% to 10%. HylaFast’s PMA was deemed not approvable, while Integrity revenue grew more than 30% year over year.

6 source passages
welcome to Anika's third quarter earnings conference call. During the quarter, total revenue was $30.6 million, up 10% from $27.8 million. Gross margin was 62% compared with 56% last year and 65% in the second quarter. We are raising the lower end of the full year 2026 total company revenue growth guidance to 6% to 10%, from 5% to 10% previously, while updating the expected contribution from each channel. In October, we received formal notification from the FDA that our HylaFast PMA is not approvable based primarily on the clinical data included in the submission. Integrity grew more than 30% year-over-year, and it increased sequentially. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue 30,594 thousand USD; net loss 311 thousand

Anika Therapeutics reported revenue of 30,594 thousand U.S. dollars and a net loss of 311 thousand U.S. dollars for the three months ended September 30, 2026.

Revenue $30.59M ▲ 10.0% Net loss $311K Diluted EPS -$0.02
Read from the first part of this long document
4 source passages
Anika Therapeutics, Inc. (the “Company”) is a global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations. For the Three Months Ended<br>September 30, | 2026 | 2025 Revenue | 30,594 | 27,817 Net loss | (311) | (2,329) Open the document at this passage
Nov 6
Current report 8-K
Revenue rises 10%; 2026 outlook raised, Hyalofast application not approvable

Anika Therapeutics reported third-quarter revenue of $30.6 million, up 10% year over year, raised 2026 revenue guidance to 6% to 10% and adjusted EBITDA margin guidance to 15% to 17%, while receiving FDA notice that Hyalofast PMA application was not approvable.

Financial results
5 source passages
Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026. Total revenue for the third quarter was $30.6 million, compared with $27.8 million in the prior-year period, representing 10% year over year growth. Total Company revenue growth: 6% to 10%, compared to 5% to 10% previously Adjusted EBITDA margin: 15% to 17%, compared to 13% to 17% previously In October, Anika received formal notification from the U.S. Food and Drug Administration (FDA) that its Hyalofast PMA application is not approvable, primarily based on the clinical data included in the submission. Open the document at this passage
Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $32.61M ▲ 15.6% Net income $3.31M Diluted EPS $0.24
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$123.43M
Trailing 12 months
Net income (TTM)
−$1.77M
Trailing 12 months
Revenue growth YoY
+10.0%
Year over year
Operating margin
-2.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
1.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$44.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-7.2%
Year over year · fewer shares
Price change (1Y)
+40.8%
Trailing year
Short interest
2.4%
Latest settlement · 3.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 6, 2026
Q3 FY26

TL;DR. Anika reported 10% third-quarter revenue growth, improved profitability, $45.0 million of cash, expanded Integrity adoption, increased manufacturing output, advanced Cingal, secured improved Hyvisc economics and reintroduced Hyalomatrix, while raising the lower ends of several 2026 guidance ranges. Risks include the non-approvable Hyalofast PMA, lower Commercial Channel guidance, reduced operating cash flow, sequential gross-margin pressure and modest 2027 growth guidance that includes expected pricing declines.

Bullish
  • + Integrity revenue increased more than 30% year over year and 37% year to date, with adoption expanding into foot, ankle and knee applications.
  • + Manufacturing output expanded, with cross-link-line volumes more than 50% above 2022 levels and further capacity growth planned.
  • + Cingal bioequivalence enrollment was completed early, and the NDA is expected before year-end 2027.
Bearish
  • − The FDA found the Hyalofast PMA application not approvable based primarily on its submitted clinical data.
  • − Nine-month operating cash flow fell to $2.8 million from $6.6 million because of inventory and capacity investments.
  • − Gross margin declined sequentially from 65% in the second quarter to 62% in the third quarter.
  • − The 2027 outlook provides only flat-to-5% total company revenue growth and includes expected U.S. OA pricing declines and flat-to-modestly-lower OEM revenue.
  • − The fourth-quarter commercial outlook is not expected to recover the summer softness in U.S. elective surgical procedures.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −29%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 35%
mid-range
Momentum
relative strength
Weak
1-month return −34%
trailing
6-month return −6%
trailing
YTD return +42%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $19 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.42% of shares out · ▼ -11.5% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
139 holders — near 3-yr high, broad support
Squeeze score 42
elevated · 0–100
Fundamentals
Excellent
Revenue growth −6%
Y/Y
Gross margin 57%
contracting
EPS growth +80%
Y/Y
Free cash flow $4.4M
Buyback $10.0M
remaining
Balance sheet $57.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −42%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 0 of last 2
Latest guidance · from the Earnings Call filed Nov 6, 2026
full year 2026
Total company revenue growth 6% – 10%
OEM channel revenue growth Raised 5% – 9%
Jul 29, 2026 0% – 5% changed to Nov 6, 2026 5% – 9%
Adjusted EBITDA margin Non-GAAP Raised 15% – 17%
Jul 29, 2026 13% – 17% changed to Nov 6, 2026 15% – 17%
Commercial channel growth 9% – 13%
Impact on adjusted EBITDA from investment in regenerative soluti Non-GAAP $8M
2027
Commercial channel revenue growth Lowered 5% – 10%
Jul 29, 2026 5% – 15% changed to Nov 6, 2026 5% – 10%
Previous outlook earlier release · from the 8-K filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Total Company Revenue Guidance · full-year 2026 5% – 10%
Prior guidance period ended · from the 8-K filed Jan 8, 2026
Commercial Channel revenue · year ended December 31, 2025 $47M – $49.5M
OEM Channel revenue · year ended December 31, 2025 $62M – $65M
Guided vs delivered · last 2 settled
Revenue for fiscal 2024 fiscal 2024
guided $168M – $173M
$119.91M Miss −29.7%
Overall revenue fiscal year 2023
guided $164M – $166M
$120.79M Miss −26.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
35% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $19 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.42% of shares out · ▼ -11.5% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
139 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $14 · 35% Range high $22
vs 200-day avg -17% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted income (loss) from continuing operations per share non-GAAP $1.18 For the Nine Months Ended September 30, 2026 —
Adjusted EBITDA non-GAAP 16.48M For the Nine Months Ended September 30, 2026 —
Adjusted net income (loss) from continuing operations non-GAAP 15.89M For the Nine Months Ended September 30, 2026 —
Commercial Channel revenue $14M third quarter of 2026 —
Commercial Channel revenue growth 17% third quarter of 2026 —
Integrity revenue $7.5M trailing 12 months —
Integrity revenue growth 37% year to date —
OEM Channel revenue growth 5% third quarter of 2026 —
Regenerative Solutions revenue growth 12% third quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANIK
Anika Therapeutics, Inc.
this stock
$182.44M +41.7% -5.9% — 2.4%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
139
% held
90.2%
Net QoQ
-150.1K sh
Top holder
Caligan Partners LP
Held Float
View
Held by Funds
Fund positions
168
View
Short & Settlement
Short Interest Falling
Shares short
323.5K
Days to cover
3.1d
Change
-42.2K sh
View
Short Volume
Short vol %
56%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
55
Value
$1.1K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
30.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Tom Malinowski
Amount
$0–$15.0K
Traded
Feb 26, 2020
View
Financials
Financials
Revenue (FY)
$112.8M
Net income (FY)
$-10.9M
EPS diluted
$-0.76
View
Buybacks
Authorized
$40.0M
Remaining
$10.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
16

Anika Therapeutics reported revenue of 30,594 thousand U.S. dollars and a net loss of 311 thousand U.S. dollars for the three months ended September 30, 2026.

View
Proposed Sales
Value
$355.3K
Shares
16.9K
Filed
Aug 7, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
Anika Reports Third Quarter 2026…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
ANIK -2.4% -33.9% -6.3% -35.0% +41.7%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.5% -28.3% -2.8% -31.6% +34.7%

Capital returns

Buyback program · as of Apr 30, 2026
Authorized
$40.00M
Spent (derived)
$30.00M
Remaining
$10.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 898437 CUSIP 035255108 13F (30d) 141 filings 126 filers Visit website Investor relations